RT Journal Article
SR Electronic
T1 Inpatient outcomes for hospitalized older adults with rhinovirus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.09.21255232
DO 10.1101/2021.04.09.21255232
A1 Del Corpo, Olivier
A1 McDonald, Emily G.
A1 Smyth, Luisa
A1 Smyth, Elizabeth
A1 Walji, Moneeza
A1 Cheng, Matthew P.
A1 Frenette, Charles
A1 Saleh, Ramy R.
A1 Lee, Todd C.
YR 2021
UL http://medrxiv.org/content/early/2021/04/13/2021.04.09.21255232.abstract
AB Background Rhinoviruses account for many cases of the “common cold” and infection is often self-limiting. As such, there is a lack of data regarding the inpatient outcomes of individuals hospitalized with rhinovirus infection. Given the generalized poorer prognosis of elderly admitted with respiratory viral infections, we assessed the mortality rate of general medical patients admitted with rhinovirus infection along with the major risk factors associated to mortality.Methods We performed a retrospective chart review of patients admitted to our clinical teaching ward from December 2013 to June 2017.Results Overall, 12.5% of patients admitted with rhinovirus infection died within 90 days of admission. The median age of admitted patients was 70 years-old. In univariable analysis, age (OR 1.05; 95% confidence interval (CI) 1.01-1.09) and the need for oxygen at presentation (OR 3.23; 95% CI 1.06-9.86) were associated with death while obstructive pulmonary disease or asthma (OR 0.10; 95% CI 0.01-0.81) was associated with survival. In the multivariable model, age (aOR 1.04; 95% CI 1.00-1.09) and obstructive lung disease (aOR 0.09 95%CI 0.01-0.73) remained significant whereas the requirement for oxygen at presentation did not (aOR 2.78; 95% CI 0.84-9.23).Conclusion Our study reveals that rhinovirus is an important cause of both morbidity and mortality in the elderly and further highlights the need for studies of potentially effective treatment options. In the meantime, we suggest that rigorous respiratory hygiene measures and quality older adult care should be practiced when caring for at-risk adults.Competing Interest StatementDrs. Lee and McDonald receive research salary from the Fonds de recherche du Quebec Santé. Dr. Cheng reports grants from McGill Interdisciplinary Initiative in Infection and Immunity, grants from Canadian Institutes of Health Research, during the conduct of the study; personal fees from GEn1E Lifesciences (as a member of the scientific advisory board), personal fees from nplex biosciences (as a member of the scientific advisory board), outside the submitted work.Funding StatementFunding for the McGill Clinical Teaching Unit cohort was provided by the McGill University Health Centre Association of Physicians.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The McGill University Health Centre Research Ethics Board approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request